Insulin Aspart — Membership Pricing

Other medications in Diabetes & Metabolism

• Insulin Degludec
• Insulin Detemir
• Insulin Glargine
• Insulin Lispro
• Linagliptin
• Liraglutide
• Liraglutide (Obesity)
• Metformin

About Insulin Aspart

Insulin aspart is a fast-acting insulin used to manage blood sugar levels in people with diabetes. It's a crucial medication for many, but its cost can be a concern. TheDrugClub is dedicated to helping our members access essential prescriptions like insulin aspart more affordably, offering significant savings to support your health journey.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Insulin Aspart is approved for (FDA label)

NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins in NOVOLOG MIX 70/30 are fixed and do not allow for basal versus prandial dose adjustments. NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis.

Source: Read the full FDA label on DailyMed. Label effective date: May 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Insulin Aspart (FDA label)

Injectable suspension: 100 units/mL (U-100) of NOVOLOG MIX 70/30, 70% insulin aspart protamine and 30% insulin aspart, is a white and cloudy suspension available as: 3 mL single-patient-use FlexPen prefilled pen Injectable suspension: 100 units/mL (U-100) of NOVOLOG MIX 70/30, 70% insulin aspart protamine and 30% insulin aspart available as: 3 mL single-patient-use FlexPen prefilled pen ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 66da64f7-ca50-47d2-95fa-de37005eef85. SPL document ID: 521a565a-0a44-0a60-e063-6394a90abf13. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Insulin Aspart (FDA label)

The following adverse reactions are also discussed elsewhere: Hypoglycemia [ see Warnings and Precautions (5.3) ] Hypoglycemia Due to Medication Errors [ see Warnings and Precautions (5.4) ] Hypersensitivity reactions [ see Warnings and Precautions (5.5) ] Hypokalemia [ see Warnings and Precautions (5.6) ] Adverse reactions observed with insulin therapy include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash and pruritus (6) . To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Clinical trials are conducted under widely varying designs, therefore, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 66da64f7-ca50-47d2-95fa-de37005eef85. SPL document ID: 521a565a-0a44-0a60-e063-6394a90abf13. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Insulin Aspart (FDA label)

NOVOLOG MIX 70/30 is contraindicated: During episodes of hypoglycemia [ see Warnings and Precautions (5.3) ] In patients with hypersensitivity to NOVOLOG MIX 70/30 or one of its excipients [see Warnings and Precautions (5.5)] Do not use during episodes of hypoglycemia (4) . Do not use in patients with hypersensitivity to NOVOLOG MIX 70/30 or one of its excipients (4) .

Source: FDA prescribing information (DailyMed). Set ID: 66da64f7-ca50-47d2-95fa-de37005eef85. SPL document ID: 521a565a-0a44-0a60-e063-6394a90abf13. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Insulin Aspart (FDA label)

Never share a NOVOLOG MIX 70/30 FlexPen between patients, even if the needle is changed (5.1) . Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring (5.2) . Hypoglycemia: May be life-threatening. Increase frequency of glucose monitoring with changes to: insulin dosage, concomitantly administered glucose lowering medications, meal pattern, physical activity; and in patients with renal or hepatic impairments and hypoglycemia unawareness (5.3) . Medication Errors: Accidental mix-ups between insulin products can occur. Instruct patients to check insulin labels before injection (5.4) . Hypersensitivity reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur. Discontinue NOVOLOG MIX 70/30, treat, and monitor, if indicated (5.5) . Hypokalemia: May be life-threatening.

Source: FDA prescribing information (DailyMed). Set ID: 66da64f7-ca50-47d2-95fa-de37005eef85. SPL document ID: 521a565a-0a44-0a60-e063-6394a90abf13. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Insulin Aspart (FDA label)

The table below presents clinically significant drug interactions with NOVOLOG MIX 70/30. Table 3: Clinically Significant Drug Interactions with NOVOLOG MIX 70/30 Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG MIX 70/30 is concomitantly administered with these drugs. Drugs that May Decrease the Blood Glucose Lowering Effect of NOVOLOG MIX 70/30 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG MIX 70/30 is concomitantly administered with these drugs.

Source: FDA prescribing information (DailyMed). Set ID: 66da64f7-ca50-47d2-95fa-de37005eef85. SPL document ID: 521a565a-0a44-0a60-e063-6394a90abf13. Label effective date: May 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.